Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Roche Holding (SWX:ROG) is back in focus after the US FDA accepted its New Drug Application for giredestrant in advanced ER positive breast cancer, alongside positive phase III data for Gazyva in primary membranous nephropathy.
See our latest analysis for Roche Holding.
Roche Holding’s recent product milestones appear to have coincided with a pickup in momentum, with a 30 day share price return of 7.44% and a 90 day share price return of 19.53%. The 1 year total shareholder return sits at 29.09%, signalling medium term performance alongside longer term total shareholder returns over 3 and 5 years.
If this kind of late stage pipeline news has your attention, it could be a good moment to scan our list of 113 healthcare AI stocks as another way to find healthcare names exposed to advanced therapies and diagnostics.
With shares up strongly over the past year, a value score of 5, and an estimated intrinsic value suggesting a sizable discount, investors now have to ask: Is Roche still mispriced, or is the market already accounting for future growth?
Against a last close of CHF374, the most widely followed narrative from Clive_Thompson pegs Roche Holding’s fair value at about CHF430, using a detailed cash flow and earnings framework.
With an additional 10 Phase III readouts expected in 2026, there are multiple opportunities for further positive news flow. Unlike many of its peers, Roche does not face a major patent cliff in the near term, providing a stable foundation for growth as new product launches contribute meaningfully without needing to offset a steep revenue decline.
Curious what underpins that CHF430 figure? The narrative leans heavily on future cash generation, steady earnings growth and a valuation multiple usually reserved for higher growth names. The exact mix of assumptions might surprise you.
Result: Fair Value of CHF430 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this hinges on key pipeline bets. Any clinical setback or tougher competition in obesity or oncology could quickly challenge the CHF430 fair value story.
Find out about the key risks to this Roche Holding narrative.
Interested but not entirely convinced by the narrative so far? Take a closer look at the numbers yourself and weigh up the balance of risks and rewards, starting with 5 key rewards and 1 important warning sign.
If Roche has sharpened your interest, do not stop here. Use the screener to find other opportunities that match your style before the market moves on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com